Heparin pharmacokinetics during hemodialysis. 1989

R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
Department of Pharmacy, Greensboro Area Health Education Center, Moses H. Cone Memorial Hospital, North Carolina.

The disposition of heparin was studied in 21 chronic hemodialysis patients. Heparin was administered as a bolus injection in doses of 3,000-12,000 U. Combined zero and first-order elimination was demonstrated, with heparin half-life declining by 74% over 3.5 h during dialysis. Assumption of a first-order pharmacokinetic model of elimination resulted in a mean difference of 0.001 U/ml between actual and predicted heparin concentrations. Mean first-order pharmacokinetic parameters were: half-life, 117 min; heparin volume of distribution (V), 68 ml/kg; clearance, 28 ml/min. A high degree of interpatient variability was also observed. A comparison of V and plasma volume (PV) revealed V to be significantly greater than PV (p less than 0.001), indicating distribution outside the plasma compartment. When compared to blood volume, there was no significant difference (p greater than 0.1), indicating that blood volume may be used to approximate V. The nonlinear component of the elimination process is not clinically significant within the range of therapeutic plasma concentrations used during hemodialysis, but the high degree of interpatient variability indicates that dosage individualization may be useful.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
January 1985, The Journal of laboratory and clinical medicine,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
April 1984, Clinical nephrology,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
January 1982, Transactions - American Society for Artificial Internal Organs,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
November 1984, Nihon Jinzo Gakkai shi,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
April 1981, Antimicrobial agents and chemotherapy,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
July 1974, Kidney international,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
August 1973, International journal of clinical pharmacology, therapy and toxicology,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
January 1977, Chemotherapy,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
June 1997, Kidney international,
R J Kandrotas, and P Gal, and J B Douglas, and J Deterding
December 1993, Recenti progressi in medicina,
Copied contents to your clipboard!